^
    Back
    Association details:
    Biomarker:FOLR1 expression
    Cancer:Ovarian Cancer
    Drug:Elahere (mirvetuximab soravtansine-gynx) (Microtubule inhibitor, Folate receptor 1-targeted antibody-drug conjugate)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: A2 - Guideline
    New
    Source:
    NCCN
    Excerpt:
    Acceptable Recurrence Therapies for Epithelial Ovarian (including LCOC)/Fallopian Tube/Primary Peritoneal Cancer….Recurrence Therapy for Platinum-Resistant Disease….Preferred Regimens...Targeted Therapy added: Mirvetuximab soravtansine-gynx (for FRα expressing tumors).
    Evidence Level:
    Sensitive: B - Late Trials
    Source:
    Ann Oncol
    Title:

    Phase III, randomized trial of mirvetuximab soravtansine versus chemotherapy in patients with platinum-resistant ovarian cancer: primary analysis of FORWARD I

    Published date:
    03/01/2021
    Excerpt:
    Superior outcomes for mirvetuximab soravtansine over chemotherapy were observed in all secondary endpoints in the FRα high population including improved objective response rate (24% v 10%), CA-125 responses (53% v 25%), and patient reported outcomes (27% v 13%)...
    DOI:
    10.1016/j.annonc.2021.02.017
    Trial ID:
    FORWARD I
    Evidence Level:
    Sensitive: C2 – Inclusion Criteria
    New
    Go to data
    Source:
    clinicaltrials.gov
    Title:

    A Study of Mirvetuximab Soravtansine vs. Investigator's Choice of Chemotherapy in Women With Folate Receptor (FR) Alpha Positive Advanced Epithelial Ovarian Cancer (EOC), Primary Peritoneal or Fallopian Tube Cancer (FORWARD I)

    Excerpt:
    ...Participants must have folate receptor alpha positive tumor expression as defined in the protocol...
    Trial ID:
    FORWARD I
    Evidence Level:
    Sensitive: C3 – Early Trials
    Source:
    Crit Rev Oncol Hematol
    Title:

    Efficacy and safety of mirvetuximab soravtansine in recurrent ovarian cancer with FRa positive expression: a systematic review and meta-analysis

    Published date:
    12/18/2023
    Excerpt:
    To evaluate the efficacy and safety of mirvetuximab soravtansine in treating recurrent ovarian cancer with folate receptor alpha (FRa) expression....Similarly, the disease control rate (DCR) was 88% (95% CI: 84%–91%). Furthermore, the median progression-free survival (PFS) was determined to be 6.1 months (95% CI: 4.27–7.47). The overall response rate and PFS for platinum-resistant ovarian cancer were found to be 29% (95% CI: 25%–32%) and 6.26 months (95% CI: 4.67–7.85), respectively.
    DOI:
    https://doi.org/10.1016/j.critrevonc.2023.104230
    Evidence Level:
    Sensitive: C3 – Early Trials
    Source:
    IGCS 2022
    Title:

    MIRVETUXIMAB SORAVTANSINE AND CARBOPLATIN FOR TREATMENT OF PATIENTS WITH RECURRENT FOLATE RECEPTOR ALPHA-POSITIVE PLATINUM-SENSITIVE OVARIAN CANCER: A FINAL ANALYSIS

    Published date:
    09/08/2022
    Excerpt:
    Ten patients received MIRV 6 mg/kg AIBW and carbo AUC5. Anti-tumor activity was observed in all dose escalation cohorts with varying levels of FRα expression. Patients receiving MIRV 6 mg/kg AIBW and carbo AUC5 had an ORR of 89%, mDOR of 12.1, and mPFS of 16.5 months...MIRV and carbo demonstrated anti-tumor activity in patients with recurrent FRα-positive PSOC.
    Secondary therapy:
    carboplatin